Doubtful debt hits Sigma earnings

Sigma Pharmaceuticals’ full-year earnings are expected to hit just over $100 million, a growth of 12% on the previous year.

However, the growth in EBIT (earnings before interest and tax) for the 12 months to 31 January could effectively be lost as the company posts a one-off accounting adjustment of $20 million.